Detalles de la búsqueda
1.
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
Ann Oncol
; 34(2): 173-185, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36414192
2.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Ann Oncol
; 33(11): 1168-1178, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973665
3.
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
Ann Oncol
; 33(5): 466-487, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35176458
4.
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
Ann Oncol
; 31(6): 798-806, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32209338
5.
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Ann Oncol
; 30(2): 290-296, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30535340
6.
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Ann Oncol
; 29(suppl_1): i10-i19, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29462254
7.
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Ann Oncol
; 29(8): 1701-1709, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29905778
8.
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Ann Oncol
; 28(12): 2932-2942, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28950290
9.
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Ann Oncol
; 28(2): 270-277, 2017 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28426106
10.
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ann Oncol
; 27(3): 423-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26768165
11.
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
Ann Oncol
; 27(8): 1573-9, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27207107
12.
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Ann Oncol
; 25(8): 1475-84, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24669016
13.
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Ann Oncol
; 30(2): 161-165, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30624547
14.
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
ESMO Open
; 8(4): 101580, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37390764
15.
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
ESMO Open
; 8(4): 101587, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37356358
16.
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
ESMO Open
; 8(6): 102065, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37988950
17.
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.
Br J Cancer
; 106(8): 1379-85, 2012 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22491421
18.
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
ESMO Open
; 7(2): 100410, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35247871
19.
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.
ESMO Open
; 7(2): 100399, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35202954
20.
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform.
Sci Rep
; 12(1): 8342, 2022 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35585228